Phenytoin-induced serum copper and ceruloplasmin in C57BL/6J mice of different ages
- 30 Downloads
Phenytoin (diphenyihydantoln) given orally to male C57BL/6J mice increased the serum copper and ceruloplasmin concentrations. Young adult mice showed a maximum increase of 107% in ceruloplasmin accompanied by a 102% increase in copper. The ceruloplasmin of middle-aged mice increased 53% and the copper 64%. For old mice the corresponding increases were 20 and 21%. Phenytoin was toxic to old mice, and middle-aged mice experienced a higher rate of death when given phenytoin for 167 days.
After 14 days, phenytoin decreased liver copper by 18% without significantly changing copper levels in kidney, brain or heart. Feeding phenytoin for 167 days lowered liver copper by 14%, increased kidney by 9% and brain by 25%. Copper in the heart remained unchanged.
We proposed that the status of copper in the brain may be important in epilepsy.
KeywordsCopper Adult Mouse Maximum Increase Copper Level Serum Copper
Unable to display preview. Download preview PDF.
- 1.Woodbury, D.M., and Fingl, E.: Drugs effective in the therapy of the epilepsies, in the Pharmacological Basis of Therapeutics, edited by Goodman, L.S., and Gilman, A., 5th edition, MacMillan Pub. Co., New York, 1975, pp. 201–226.Google Scholar
- 2.Peter, T., Ross, D., Duffield, A., Luxton, M., Harper, R., Hunt, D., and Sloman, G.: Effect on survival after myocardial infarction of long-term treatment with phenytoin. British Heart J., 40:1356–1360, 1978.Google Scholar
- 7.Lifschitz, M.D., and Henkin, R.I.: Circadian variation in copper and zinc in man. J. Applied Physiol., 31:88–92, 1971.Google Scholar
- 8.Dowdy, R.P., and Dohm, G.L.: Effect of training and exercise in serum ceruloplasmin in rats. Proc. Soc. Exp. Biol. and Med., 139:489-491, 1972.Google Scholar
- 9.Davidoff, G.N., Votaw, M.L., Coon, W.W., Hultquist, D.E., Filter, B.J., and Wexler, S.A.: Elevations in serum copper, erythrocyte copper, and ceruloplasmin concentrations in smokers. Am. J. Clin. Pathol., 70:790–792, 1976.Google Scholar
- 10.Shields, G.S., Markowitz, H., Cartwright, G.E., and Wintrobe, M.M.: Blood copper proteins in human Subjects, in Metal Binding in Medicine, edited by Seven, M.J. and Johnson, L.A., Lippincott Co., Philadelphia, 1960, pp. 259–264.Google Scholar
- 11.Alginger, P., Kolarz, G., and Willvonseder, R.: Copper in ankylosing spondylitis and rheumatoid arthritis. Scand. J. Rheumantology., 7:75–78, 1978.Google Scholar
- 12.Viersieck, J., Barbier, F., Speecke, A., and Hoste, J.: Influence of myocardial infarction on serum manganese, copper, and zinc concentrations. Clin. Chem., 21:578–581, 1975.Google Scholar
- 13.Harman, D.: Role of serum copper in coronary atherosclerosis. Circulation, 28:658, 1963.Google Scholar
- 14.Bustamento, J., Martin, M.C., Fernandez, J., and Ortiz, O.: Zinc, copper and ceruloplasmin in arteriosclerosis. Biomedicine, 25:244–245, 1976.Google Scholar
- 20.Massie, H.R., Colacicco, J.R., and Aiello, V.R.: Changes with age in copper and ceruloplasmin in serum from humans and C57BL/6J mice. Age, 2:97–101, 1979.Google Scholar
- 25.Keen, C.L., and Hurley, L.S.: Superoxide dismutase activity in the crinkled mutant mouse: ameliorative effects of dietary copper supplementation. Proc. Soc. Exp. Biol. and Med., 162: 152–156, 1979.Google Scholar